ORBi: Ribbens Clio - Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis

Reference : Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Rheumatology
	To cite this reference:	http://hdl.handle.net/2268/94580

Title :	Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis
Language :	English
Author, co-author :	Ribbens, Clio [Université de Liège - ULg > > Rhumatologie >]
	Andre, Béatrice [Université de Liège - ULg > > Rhumatologie - Néphrologie >]
	Jaspar, J. M. [ > > ]
	Kaye, O. [ > > ]
	Kaiser, Marie-Joëlle [Université de Liège - ULg > > Rhumatologie >]
	De Groote, D. [ > > ]
	Malaise, Michel [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >]
Publication date :	2000
Journal title :	Journal of Rheumatology
Publisher :	Journal of Rheumatology Publishing Company
Volume :	120
Issue/season :	1
Pages :	888-893
Audience :	International
ISSN :	0315-162X
City :	Toronto
Country :	Canada
Keywords :	[en] Non-Steroidal Anti-Inflammatory Agents ; Antirheumatic Agents ; Indoles ; Interleukin-6 ; Matrix Metalloproteinase 3 ; C-Reactive Protein
Abstract :	[en] OBJECTIVE: To demonstrate that serum matrix metalloproteinase-3 (MMP-3) is a variable associated with disease activity and with the response to treatment in rheumatoid arthritis (RA). METHODS: Serum MMP-3 levels were measured and compared to biological and clinical disease activity variables in 20 patients with active RA assessed serially during a one year prospective open label trial with methotrexate or tenidap. RESULTS: MMP-3 levels were significantly correlated with C-reactive protein (CRP) and interleukin 6 serum levels as well as with the disease activity score (DAS), not only at start in untreated patients but also during the 12 month followup period in both treated groups. Early changes (after 0.5, 1, 2, or 3 months) in MMP-3 levels were significantly associated with change in DAS observed 4 to 6 months later. CONCLUSION: In addition to CRP, a systemic marker of inflammation, serum MMP-3 may serve as a consistent synovial derived marker of RA disease activity, early changes of which predict disease outcome.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/94580

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	Malaise_2000_JRheumatol_888-893.pdf		Publisher postprint	495.49 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5